Bioventix (LON:BVXP – Get Free Report) posted its quarterly earnings results on Monday. The biotechnology company reported GBX 145.74 earnings per share for the quarter, Digital Look Earnings reports. The firm had revenue of GBX 1,297 million during the quarter. Bioventix had a return on equity of 65.83% and a net margin of 59.30%.
Bioventix Price Performance
Bioventix stock opened at GBX 2,050 on Tuesday. Bioventix has a one year low of GBX 1,300 and a one year high of GBX 2,255. The stock has a market capitalization of £107.11 million, a PE ratio of 14.59 and a beta of 0.54. The business’s fifty day moving average is GBX 1,694.82 and its 200 day moving average is GBX 1,656.41.
Bioventix Company Profile
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
Read More
- Five stocks we like better than Bioventix
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
Receive News & Ratings for Bioventix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix and related companies with MarketBeat.com's FREE daily email newsletter.
